Skip to content

13F-HR filed by Omega Fund Management, LLC

Omega Fund Management, LLC filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-14, with 11 holding rows worth $155,010,742.

Accession
0000950123-24-005045
Filed
2024-05-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2024

A holdings report, 11 entries on the cover page, a total value of $155,010,742 stated on the cover page (in dollars after the unit check, H1), rows summing to $155,010,742 with VALUE read as dollars as filed, 13F file number 028-16844. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
NUVATION BIO INC COM CL A67080N101Stock14,072,340$51,223,318dollars as filed
LEXEO THERAPEUTICS INC52886X107COMMON STOCK2,355,904$36,940,575dollars as filed
REPLIMUNE GROUP INC76029N106COMMON STOCK3,001,319$24,520,776dollars as filed
ENGENE HOLDINGS INC29286M105COM1,076,357$18,244,251dollars as filed
SANA BIOTECHNOLOGY INC799566104COM843,750$8,437,500dollars as filed
MORPHIC HLDG INC61775R105COM159,846$5,626,579dollars as filed
IKENA ONCOLOGY INC45175G108COM2,249,123$3,193,755dollars as filed
IMMUNIC INC4525EP101COM1,788,160$2,360,371dollars as filed
ENGENE HOLDINGS INC29286M113W EXP 10/31/2028360,903$1,876,696dollars as filed
SYROS PHARMACEUTICALS INC87184Q206COM NEW251,270$1,344,295dollars as filed
KRONOS BIO INC50107A104COM955,866$1,242,626dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-24-005045this filing2024-05-14acceptance time not in the bulk data set